FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004931703> ?p ?o ?g. }

• W2004931703 endingPage "865" @default.
• W2004931703 startingPage "859" @default.
• W2004931703 abstract "BACKGROUND Tumor-induced osteolysis due to breast carcinoma and myeloma is responsible for a considerable morbidity that severely impairs patients'quality of life. Osteoclast-mediated bone resorption is reported to be increased markedly in patients with tumor bone disease and can be inhibited by bisphosphonate therapy. METHODS The incidence of skeletal complications and the effectiveness of bisphosphonate therapy in patients with breast carcinoma metastatic to bone or in those with myeloma were derived from large-scale, long-term, placebo-controlled trials with clodronate or pamidronate. To the authors' knowledge, there are few studies published to date evaluating the cost-effectiveness of bisphosphonate therapy, and the majority that do exist often are based on models and are applicable only to a particular health care system. RESULTS From the placebo groups of the above-mentioned trials, one can estimate that approximately 25–40% of the patients with breast carcinoma metastatic to bone will require radiotherapy for bone pain and approximately 17–50% will sustain incident vertebral fractures yearly. The incidence of complications is reported to be lower in myeloma patients. The prolonged administration of bisphosphonates reportedly can reduce the frequency of skeletal-related events by approximately 25–50%. Maximal efficacy appears to have been achieved with the current therapeutic schemes based on monthly intravenous infusions. Beneficial effects appear to be obtained more readily using the intravenous route rather than the oral route. The costs of bisphosphonate therapy appear to be higher than the cost savings from the prevention of skeletal-related events. The costs per quality of life-adjusted year have been estimated to be > $100,000, but more research is needed. Limited data suggest that zoledronic acid will not reduce treatment costs but the short infusion time will lead to substantial time savings for patients and for outpatient oncology facilities. CONCLUSIONS As is the case for many agents used in oncology, bisphosphonates remain a relatively expensive therapy. More studies are needed to evaluate their cost-effectiveness ratio correctly. A ceiling effect has been reached with current therapeutic schemes and tailoring therapy to the individual patient needs to be evaluated correctly to increase therapeutic effectiveness and improve quality of life further without increasing treatment costs. Cancer 2003;97(3 Suppl):859–65. © 2003 American Cancer Society. DOI 10.1002/cncr.11139" @default.
• W2004931703 created "2016-06-24" @default.
• W2004931703 creator A5053293171 @default.
• W2004931703 date "2003-01-23" @default.
• W2004931703 modified "2023-10-17" @default.
• W2004931703 title "Effectiveness and cost of bisphosphonate therapy in tumor bone disease" @default.
• W2004931703 cites W1530002712 @default.
• W2004931703 cites W1768011742 @default.
• W2004931703 cites W1842425533 @default.
• W2004931703 cites W1906721103 @default.
• W2004931703 cites W1932993947 @default.
• W2004931703 cites W1937662086 @default.
• W2004931703 cites W1951349736 @default.
• W2004931703 cites W1954585625 @default.
• W2004931703 cites W1967875617 @default.
• W2004931703 cites W1968511145 @default.
• W2004931703 cites W1971047116 @default.
• W2004931703 cites W1974568982 @default.
• W2004931703 cites W1989622431 @default.
• W2004931703 cites W1990711952 @default.
• W2004931703 cites W1993952498 @default.
• W2004931703 cites W1994182611 @default.
• W2004931703 cites W2000096438 @default.
• W2004931703 cites W2001670154 @default.
• W2004931703 cites W2008756438 @default.
• W2004931703 cites W2052104719 @default.
• W2004931703 cites W2054351138 @default.
• W2004931703 cites W2065672662 @default.
• W2004931703 cites W2122560580 @default.
• W2004931703 cites W4214641845 @default.
• W2004931703 cites W4295846566 @default.
• W2004931703 doi "https://doi.org/10.1002/cncr.11139" @default.
• W2004931703 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12548587" @default.
• W2004931703 hasPublicationYear "2003" @default.
• W2004931703 type Work @default.
• W2004931703 sameAs 2004931703 @default.
• W2004931703 citedByCount "69" @default.
• W2004931703 countsByYear W20049317032012 @default.
• W2004931703 countsByYear W20049317032013 @default.
• W2004931703 countsByYear W20049317032014 @default.
• W2004931703 countsByYear W20049317032015 @default.
• W2004931703 countsByYear W20049317032016 @default.
• W2004931703 countsByYear W20049317032018 @default.
• W2004931703 countsByYear W20049317032020 @default.
• W2004931703 crossrefType "journal-article" @default.
• W2004931703 hasAuthorship W2004931703A5053293171 @default.
• W2004931703 hasConcept C121608353 @default.
• W2004931703 hasConcept C126322002 @default.
• W2004931703 hasConcept C141071460 @default.
• W2004931703 hasConcept C142724271 @default.
• W2004931703 hasConcept C143998085 @default.
• W2004931703 hasConcept C170493617 @default.
• W2004931703 hasConcept C204787440 @default.
• W2004931703 hasConcept C27081682 @default.
• W2004931703 hasConcept C2776033226 @default.
• W2004931703 hasConcept C2776139714 @default.
• W2004931703 hasConcept C2776169692 @default.
• W2004931703 hasConcept C2776364478 @default.
• W2004931703 hasConcept C2776541429 @default.
• W2004931703 hasConcept C2777251235 @default.
• W2004931703 hasConcept C2781282405 @default.
• W2004931703 hasConcept C3018521938 @default.
• W2004931703 hasConcept C509974204 @default.
• W2004931703 hasConcept C530470458 @default.
• W2004931703 hasConcept C673006 @default.
• W2004931703 hasConcept C71924100 @default.
• W2004931703 hasConceptScore W2004931703C121608353 @default.
• W2004931703 hasConceptScore W2004931703C126322002 @default.
• W2004931703 hasConceptScore W2004931703C141071460 @default.
• W2004931703 hasConceptScore W2004931703C142724271 @default.
• W2004931703 hasConceptScore W2004931703C143998085 @default.
• W2004931703 hasConceptScore W2004931703C170493617 @default.
• W2004931703 hasConceptScore W2004931703C204787440 @default.
• W2004931703 hasConceptScore W2004931703C27081682 @default.
• W2004931703 hasConceptScore W2004931703C2776033226 @default.
• W2004931703 hasConceptScore W2004931703C2776139714 @default.
• W2004931703 hasConceptScore W2004931703C2776169692 @default.
• W2004931703 hasConceptScore W2004931703C2776364478 @default.
• W2004931703 hasConceptScore W2004931703C2776541429 @default.
• W2004931703 hasConceptScore W2004931703C2777251235 @default.
• W2004931703 hasConceptScore W2004931703C2781282405 @default.
• W2004931703 hasConceptScore W2004931703C3018521938 @default.
• W2004931703 hasConceptScore W2004931703C509974204 @default.
• W2004931703 hasConceptScore W2004931703C530470458 @default.
• W2004931703 hasConceptScore W2004931703C673006 @default.
• W2004931703 hasConceptScore W2004931703C71924100 @default.
• W2004931703 hasIssue "S3" @default.
• W2004931703 hasLocation W20049317031 @default.
• W2004931703 hasLocation W20049317032 @default.
• W2004931703 hasOpenAccess W2004931703 @default.
• W2004931703 hasPrimaryLocation W20049317031 @default.
• W2004931703 hasRelatedWork W1927321941 @default.
• W2004931703 hasRelatedWork W2010698692 @default.
• W2004931703 hasRelatedWork W2041686004 @default.
• W2004931703 hasRelatedWork W2061216954 @default.
• W2004931703 hasRelatedWork W2092339321 @default.
• W2004931703 hasRelatedWork W2320879825 @default.
• W2004931703 hasRelatedWork W2473227341 @default.

• next